MREO
Mereo Biopharma·NASDAQ
--
--(--)
--
--(--)
4.70 / 10
Netural
The fund flow score is robust (7.5/10), reflecting positive capital inflows across all size categories. However, analyst sentiment is only moderately supportive, with a consensus of Strong Buy (60%) and Neutral (40%) from five providers, and historical win rates for these ratings are inconsistent, contributing to a neutral overall view.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
60%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-29
InstitutionLifeSci Capital
Times predicted1
Historical Win Rate0.0%
What is the market sentiment for MREO?
- MREO holds a Bearish analyst rating, with 60% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.70/10 (Netural).
